Open Access
Performance standards for antimicrobial susceptibility testing
Reads0
Chats0
TLDR
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.Abstract:
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the previous edition appear in boldface type.) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016. The data in the interpretive tables in this supplement are valid only if the methodologies in M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition are followed.read more
Citations
More filters
Journal ArticleDOI
Emergence of KPC-2 and KPC-3 in Carbapenem-Resistant Klebsiella pneumoniae Strains in an Israeli Hospital
TL;DR: A sharp increase in carbapenem-resistant Klebsiella pneumoniae strains possessing KPC in Tel Aviv Medical Center from 2004 to 2006 is noticed, indicating rapid dissemination of KPC outside the United States.
Journal ArticleDOI
Adaptive resistance to biocides in Salmonella enterica and Escherichia coli O157 and cross-resistance to antimicrobial agents.
TL;DR: Concern is raised over the indiscriminate and often inappropriate use of biocides, especially triclosan, in situations where they are unnecessary, whereby they may contribute to the development of microbial resistance mechanisms.
Journal ArticleDOI
Spread of OXA-48-Encoding Plasmid in Turkey and Beyond
Amélie Carrër,Laurent Poirel,Mesut Yilmaz,Özay Arıkan Akan,Cilli Feriha,Gaelle Cuzon,Ghassan M. Matar,Patrick Honderlick,Patrice Nordmann +8 more
TL;DR: This work highlights the current plasmid-mediated dissemination of the OXA-48 carbapenemase worldwide and identifies similar 70-kb plasmids carrying the blaOXA- 48 gene.
Journal ArticleDOI
Molecular Characterization and Epidemiology of Extended-Spectrum- β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates Causing Health Care-Associated Infection in Thailand, Where the CTX-M Family Is Endemic
TL;DR: Molecular detection and characterization of ESBL-related bla genes and pulsed-field gel electrophoresis analysis demonstrated that there was no major clonal relationship among these ESBL producers and CTX-M ESBL is highly endemic in the country.
Journal ArticleDOI
Ceftazidime-Avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M.E. Wagenlehner,Jack D. Sobel,Paul Newell,Jon Armstrong,Xiangning Huang,Gregory G. Stone,Katrina Yates,Leanne B. Gasink +7 more
TL;DR: Ceftazidime-avibactam was highly effective for empiric treatment of complicated urinary tract infection, including in patients with ceftazodime-nonsusceptible pathogens, and may offer an alternative to carbapenems in this setting.